Type 2 & other diabetes

Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients

Diabetes Res Clin PractPublished Retrospective cohort study

Main finding · New-onset dementiaResult — go to the resultHazard ratio 0.54 95 % CI 0.51–0.57

Authors' conclusion

Compared to DPP-4i, SGLT2i use is associated with a lower risk of dementia in older adults with T2DM, with consistent benefits observed across diverse populations and patient subgroups. These findings highlight the potential of SGLT2i as a preventive strategy for cognitive decline and support further investigation in randomized controlled trials.

Study context

Population
Adults aged ≥65 years with T2D who initiated SGLT2i or DPP4i between January 1, 2013, and November 30, 2024matched cohort
Participants
80,376 vs 80,376
Exposure
SGLT2i vs DPP4i initiation
  • SGLT2in = 80,376
  • DPP4in = 80,376reference
Outcome
New-onset dementia
Methodological detailspropensity-score matched, TriNetX electronic health records network
  • Propensity-score matched
  • TriNetX electronic health records network

Main finding

As reported in the abstract

Hazard ratio

0.54

95 % CI 0.51–0.57

P < 0.001

SGLT2ivs DPP4i
HR 0.54 (95 % CI 0.51–0.57); P < 0.001

Observational data: associations, not effects.

Secondary outcomes

OutcomeHR (95 % CI)P value
Dementia-related drug use0.69 (0.64–0.74)P < 0.001
Alzheimer's disease0.53 (0.48–0.60)P < 0.001
Vascular dementia0.52 (0.46–0.58)P < 0.001

Subgroup analyses

Subgroup analyses showed consistent protective effects

Original publication

Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients. Diabetes Res Clin Pract. Published 21 April 2025. doi:10.1016/j.diabres.2025.112197

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.